Thoracic Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2024-12-23 ms8000001565095549 来自辽宁

偏重的研究方向：胸外;肺癌;肿瘤
经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰

6 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2024-12-23 ms3000002977722150 来自上海

投稿命中率:50.0
偏重的研究方向：肺癌
经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容
需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。
12.6投稿
11.7under revrew
然后没有变过状态，希望能顺利通过。

9 0

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-06-05 只想毕业来自广东省

偏重的研究方向：基础实验
经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗

103 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2024-10-27 ms7000000417591078 来自天津

投稿命中率:5.0
经验分享：垃圾杂志慎投，得找关系

38 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-10-31 674889986 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：机制;肺癌;肿瘤
经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！

120 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-09-22 ms9000001053108898 来自甘肃省

审稿速度:1.0
偏重的研究方向：肺癌
经验分享：个案 2天被拒枯了

117 0

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-06-27 ms7000001609282445 来自山东省

最近还收meta分析吗

141 0

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-04-30 ms3000001340442240 来自广东省

Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR

109 0

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-03-05 ms3000001126828781 来自广西

审稿速度:1.0
经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。

115 0

[GetPortalCommentsPageByObjectIdResponse(id=2244486, encodeId=309a22444860a, content=偏重的研究方向：胸外;肺癌;肿瘤 经验分享：请问最近有投这个杂志的吗，投稿一周了还是Awaiting EIC Assignment状态，这正常吗😰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5d8857106, createdName=ms8000001565095549, createdTime=Mon Dec 23 14:27:34 CST 2024, time=2024-12-23, status=1, ipAttribution=辽宁), GetPortalCommentsPageByObjectIdResponse(id=2244585, encodeId=be4e2244585bb, content=投稿命中率:50.0 偏重的研究方向：肺癌 经验分享：投稿前做了一些准备，是一本专注于肺癌、食管癌、纵隔癌和乳腺癌等胸部恶性肿瘤研究，比较符合我的内容 需要提交原始数据，后面又看了下最近发表的文章，好像很多都是1-2个月接收，感觉质量都还挺好。 12.6投稿 11.7under revrew 然后没有变过状态，希望能顺利通过。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms3000002977722150, createdTime=Mon Dec 23 23:13:20 CST 2024, time=2024-12-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2140880, encodeId=2beb214088000, content=偏重的研究方向：基础实验 经验分享：想问下最近有投稿这个期刊的吗，审稿快不快呀，我已经投稿一周了，还没有分配编辑，这个时间正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=76135202599, createdName=只想毕业, createdTime=Mon Jun 05 11:01:03 CST 2023, time=2023-06-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2233327, encodeId=2ce6223332e0e, content=投稿命中率:5.0 经验分享：垃圾杂志慎投，得找关系, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=608c8262272, createdName=ms7000000417591078, createdTime=Sun Oct 27 00:57:58 CST 2024, time=2024-10-27, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2165916, encodeId=16492165916f1, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：机制;肺癌;肿瘤 经验分享：投稿第二天就是under revrew，然后没有变过状态，目前还没有消息。需要提交原始数据。看了下最近发表的文章，质量都不错，大概都是1-2个月接收，希望自己也会顺利！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb3118685, createdName=674889986, createdTime=Tue Oct 31 15:32:53 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159028, encodeId=b8572159028f8, content=审稿速度:1.0 偏重的研究方向：肺癌 经验分享：个案 2天被拒枯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dad8612290, createdName=ms9000001053108898, createdTime=Fri Sep 22 01:20:26 CST 2023, time=2023-09-22, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2145118, encodeId=71e0214511808, content=最近还收meta分析吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16686542389, createdName=ms7000001609282445, createdTime=Tue Jun 27 23:07:03 CST 2023, time=2023-06-27, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2129414, encodeId=7b422129414fc, content=Submissions will be subject to an APC if accepted and published in the journal: $2750 USD / £1850 GBP / €2500 EUR, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81ca5454976, createdName=ms3000001340442240, createdTime=Sun Apr 30 12:52:16 CST 2023, time=2023-04-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2117650, encodeId=032e211e650b5, content=审稿速度:1.0 经验分享：我投的生信，做了验证，第二天就拒了，感觉这个杂志应该不好中的，质量不错的。看了一下近一年这个杂志发的生信，大部分好像都是有细胞实验的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99d78274978, createdName=ms3000001126828781, createdTime=Sun Mar 05 09:55:55 CST 2023, time=2023-03-05, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2116294, encodeId=5621211629450, content=偏重的研究方向：肺癌;肿瘤 经验分享：投的meta分析，3天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=兔兔好运发paper, createdTime=Fri Feb 24 16:06:22 CST 2023, time=2023-02-24, status=1, ipAttribution=四川省)]

2023-02-24 兔兔好运发paper 来自四川省

偏重的研究方向：肺癌;肿瘤
经验分享：投的meta分析，3天被拒

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务